Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move is expected to significantly expand Full-Life’s pipeline, including two compounds nearing clinical trials, provide a second innovative peptide-focused discovery platform, and leverage its Radio Technology manufacturing and logistics platforms to advance compounds into clinical development.
Acquisition Terms
Under the terms of the acquisition, Focus-X shareholders are eligible to receive an upfront payment from Full-Life, as well as potential development, regulatory, and sales-based milestones of up to USD 245 million. Additionally, Focus-X shareholders will receive royalties on any commercial sales. The acquisition is expected to close in the first quarter of 2023.
Focus-X Profile
Founded in 2020, Focus-X has developed a proprietary engineering platform for the development of peptide radioligands that precisely deliver alpha or beta emitters to break down cancer cell DNA. The company’s two lead compounds in development include a prostate-specific membrane antigen (PSMA)-targeted peptide for the treatment of metastatic castration-resistant prostate cancer and a neurotensin receptor type 1 (NTSR1)-targeted peptide for the treatment of pancreatic cancer. The PSMA-targeted compound is currently undergoing an investigator-initiated imaging study. Focus-X also has six other programs in earlier stages of development.-Fineline Info & Tech
